Bifunctional PROTAC Compounds for Mutant EGFR Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR-targeting PROTACs are ineffective in degrading all main EGFR mutations, leading to resistance in non-small cell lung cancer treatment, as they fail to address the tertiary C797S mutation resistance obstacle.
Innovation Solution
Development of novel bifunctional compounds that conjugate EGFR inhibitor moieties with E3 ligase ligands to recruit targeted proteins to E3 ubiquitin ligase for degradation, specifically designed to target mutant EGFR kinase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current EGFR-targeting PROTACs are used, then degradation of some EGFR mutations is achieved, but resistance develops due to inability to degrade all main EGFR mutations including C797S
Solution Approach 1:
The patent applies universality by designing a PROTAC molecule that can universally target multiple EGFR mutation types (L858R, exon 19 deletion, T790M, and C797S) through a single compound. The bifunctional structure combines an EGFR inhibitor moiety that binds to the EGFR kinase domain with an E3 ligase ligand moiety that recruits the cereblon E3 ubiquitin ligase, creating a universal degradation platform effective across different mutation backgrounds.
Solution Approach 2:
The patent employs composite material principles by constructing a hybrid PROTAC molecule that integrates two distinct functional components: an EGFR inhibitor portion (such as gefitinib, erlotinib, or osimertinib derivatives) and an E3 ligase ligand portion (such as thalidomide or lenalidomide derivatives). This composite structure enables simultaneous binding to both EGFR and the E3 ligase complex, facilitating targeted protein degradation.
2Reliability
If traditional EGFR inhibitors are used, then enzymatic activity is inhibited, but protein degradation does not occur leading to resistance
Solution Approach 1:
The patent applies inversion by reversing the traditional inhibition approach. Instead of merely blocking the enzymatic activity of EGFR with small molecule inhibitors, the invention uses PROTACs to recruit E3 ubiquitin ligases that tag EGFR for degradation by the proteasome. This shifts the mechanism from preventing function (inhibition) to eliminating the target protein itself (degradation), thereby overcoming resistance.
Solution Approach 2:
The patent introduces an intermediary mechanism by employing E3 ubiquitin ligases as mediators between the PROTAC molecule and the EGFR target. The PROTAC acts as a bridge that simultaneously binds EGFR and the E3 ligase, facilitating the transfer of ubiquitin to EGFR. This intermediary approach enables selective protein degradation while maintaining specificity for mutant EGFR variants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively degrade mutant EGFR kinase, offering a potential strategy to overcome drug resistance mediated by EGFR mutations, including the C797S mutation, thereby enhancing treatment efficacy in non-small cell lung cancer.
Implementation Method 1
recruitment of the E3 ligase to the specific unwanted proteins results in ubiquitination and subsequent degradation of the target protein by the proteasome
Implementation Method 2
The whole process of ubiquitination and proteasomal degradation is known as the ubiquitin-proteasome pathway (UPP)
Data Source
AI summary
Disclosed herein are bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation of mutant EGFR kinase, and methods of preparation and uses thereof.